Valbenazine in Obsessive Compulsive Disorder
ConditionObsessive-Compulsive Disorder
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Chicago
About this trial
The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).
Eligibility criteria
Qualifiers
Men and women aged 18-65 years
Primary diagnosis of obsessive compulsive disorder (OCD)
Yale Brown Obsessive Compulsive Scale (Y-BOCS) score of at least 21 at baseline (moderate or higher severity)
Ability to understand and sign the consent form
Disqualifiers
Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
Subjects considered an immediate suicide risk based on the Columbia Suicide Severity Rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)
History of psychosis or bipolar disorder based on DSM-5 criteria
Trial design
Treatments tested in this trial
- Valbenazine
- Placebo
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
University of Chicago
Lead sponsor
Neurocrine Biosciences
Collaborator
Source ClinicalTrials.gov